Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(13):1039-1040; doi:10.1093/jnci/92.13.1039
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McCann, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCann, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 13, 1039-1040, July 5, 2000
© 2000 Oxford University Press

NEWS

Molecular Markers May Improve Colon Cancer Staging, Screening

Jean McCann

With more sophisticated tests now available, the dilemma of just who needs adjuvant treatment for colon cancer and who does not is coming to the fore.

The problem of understaging in colon cancer patients is probably worse than previously thought, based on more sophisticated methods of detecting metastases. Many patients thought to be free of disease may not be.

"The theory is that many who have stage II colon cancer may actually have stage III, and should be getting adjuvant chemotherapy," said David Ota, M.D., medical director and chief of surgical oncology . . . [Full Text of this Article]

Molecular Markers

Screening for Colon Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?